There are currently 1268 clinical trials in Seattle, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center and University of Washington Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV
NCT06013579
Recruiting
People aging with HIV are at higher risk for Alzheimer's disease and related dementias, and although physical activity is a promising target to mitigate such risk, this population engages in low levels of physical activity. Few studies have tested cognitive effects of exercise interventions or examined mechanisms of adherence to long-term exercise among diverse samples of midlife and older people with HIV. The current study will leverage an existing R01 to address these gaps and provide implicat... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
11/07/2023
Locations: University of Washington, Seattle, Washington
Conditions: HIV Infections, Cognitive Impairment
Register for Updates
Spinraza in Adult Spinal Muscular Atrophy
NCT03709784
Recruiting
This is a longitudinal, observational study of adult patients with genetically confirmed chromosome 5q SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
11/07/2023
Locations: University of Washington, Seattle, Washington
Conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type 3
Register for Updates
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
NCT05727878
Recruiting
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/06/2023
Locations: Principal Investigator, Seattle, Washington
Conditions: Persistent Corneal Epithelial Defect
Register for Updates
Linerixibat Long-term Safety, and Tolerability Study
NCT04167358
Recruiting
This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 [NCT01899703], 201000 GLIMMER [NCT02966834] (group 1) or 212620 GLISTEN [NCT00210418]) (group 2). All participants will receive open-label linerixibat for the duration of the study. The study duration is expected... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/03/2023
Locations: GSK Investigational Site, Seattle, Washington
Conditions: Cholestasis
Register for Updates
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
NCT04977024
Recruiting
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The i... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2023
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
Register for Updates
Reopening Schools Safely and Educating Youth Research Study
NCT04859699
Recruiting
The study has three aims and involves a clustered randomized controlled trial (RCT) where K-5 schools will be the unit of randomization. Aim 1 involves a qualitative assessment of rural Latino community's social, ethical, behavioral needs and resources for students to return to school and maintain onsite learning. Aim 2 includes a clustered RCT in schools. Aim 3 involves qualitative assessment of implementation outcomes of the Yakima School District (YSD) testing program and risk communication i... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
11/01/2023
Locations: University of Washington, Seattle, Washington
Conditions: Absenteeism
Register for Updates
MBCT Intervention: Healthy Mind, Healthy Living
NCT05965349
Recruiting
Depression among older Korean Americans are rising. Mindfulness-based cognitive therapy (MBCT) is an evidence-based intervention (EBI), effective for preventing depression relapse and reducing depressive symptoms. To enhance feasibility, acceptability, and reach, a brief version of MBCT has been developed and delivered by telephone (brief MBCT-T), but has only been tested in primarily White samples. This study will test test the effect of brief MBCT-T among older Korean Americans.
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
11/01/2023
Locations: University of Washington, Seattle, Washington
Conditions: Mindfulness Based Cognitive Therapy, Depression, Sleep, Anxiety Depression
Register for Updates
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
NCT04038502
Recruiting
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. P... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington
Conditions: Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Register for Updates
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
NCT03801434
Recruiting
This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: Fred Hutchinson cancer research center, Seattle, Washington
Conditions: BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Peripheral Blood White Cells, Blasts Under 20 Percent of Bone Marrow Nucleated Cells, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Eosinophilia, Hepatomegaly, Hypereosinophilic Syndrome, JAK2 Gene Mutation, Splenomegaly, TEL-JAK2 Fusion Protein Expression
Register for Updates
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
NCT02810704
Recruiting
PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/30/2023
Locations: University of Washington, Seattle, Washington
Conditions: Pulmonary Embolism, Venous Thrombosis
Register for Updates
Diabetes Education With Real-time Continuous Glucose Monitoring
NCT05394844
Recruiting
Determine the impact of the Compañeros en Salud (Partners in Health) curriculum in conjunction with RT-CGM on glycemic control in Latinx patients with T2D. Participants will be randomized to receive the Companeros en Salud diabetes self-management education and support (DSMES) intervention with or without RT-CGM
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
10/28/2023
Locations: University of Washington Diabetes Institute, Seattle, Washington +1 locations
Conditions: Diabetes Type 2
Register for Updates
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
NCT04039464
Recruiting
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
Gender:
All
Ages:
Between 3 months and 18 years
Trial Updated:
10/27/2023
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Pediatric Pulmonary Hypertension
Register for Updates